Inputs: momentum, trendVelocity
Momentum 83/100 confirmed by trend velocity 72/100.
Prediction result · Ensemble engineUpdated 3:57 AM
UTHRUnited Therapeutics Corporation stock price outlook
$598.72+0.87% since prev closeBullish
United Therapeutics Corporation (UTHR) is trading at $598.72, up 0.87% since the previous close and +1.91% over the past week. Price sits above its 50-day average by 13.59%, with price momentum at 83/100 and trend velocity at 72/100. Sentiment across 0 recent headlines reads mixed at 50/100. Volatility risk is moderate (69/100) and the stock is 94% of the way up its 52-week range. The weighted factor score lands at 78/100 — a bullish signal. Research only, not investment advice.
Universal leanmarket
UTHR
United Therapeutics Corporation
$598.72+0.87%
LEANSOFT mild bid
WHY
- United Therapeutics Corporation (UTHR) is trading at $598.72, up 0.87% since the previous close and +1.91% over the past week. Price sits above its 50-day average by 13.59%, with price momentum at 83/100 and trend velocity at 72/100. Sentiment across 0 recent headlines reads mixed at 50/100. Volatility risk is moderate (69/100) and the stock is 94% of the way up its 52-week range. The weighted factor score lands at 78/100 — a bullish signal. Research only, not investment advice.
- Bull input: Momentum 83/100 confirmed by trend velocity 72/100.
RISK
Signals are model output from public data, not personalized investment advice.
INVALIDATE
Invalidate on a decisive break of the session bid, catalyst reversal, or model edge flipping bearish.
AI Signal
Bullish · Strong bullish edge
live data
Full public-market mode: chart history, quote, and news inputs were available.
Chart feed
Cron market chart feed
Quote/history
Six-month public chart history loaded.
News feed
No relevant current headlines found.
Signal inputs
Technical factors and news sentiment evaluated across multiple signal inputs.
News Sentiment50/100
Price Momentum83/100
Trend Velocity72/100
Volatility Risk69/100
Historical Modeling: Visualized ranges are mathematically derived from historic volatility metrics, corporate filings, and option-implied volume profiles. They represent statistical points of interest for research purposes, not financial execution commands or advice.
Why It Matters
Signal Explanation
United Therapeutics Corporation (UTHR) is trading at $598.72, up 0.87% since the previous close and +1.91% over the past week. Price sits above its 50-day average by 13.59%, with price momentum at 83/100 and trend velocity at 72/100. Sentiment across 0 recent headlines reads mixed at 50/100. Volatility risk is moderate (69/100) and the stock is 94% of the way up its 52-week range. The weighted factor score lands at 78/100 — a bullish signal. Research only, not investment advice.
Analyst Engine · Specialist model ensemble
38% of trees lean bullish on UTHR
Weighted factor score across 16 signal inputs evaluating 9 features: momentum, news, volume, volatility, range, sentiment divergence, trend structure, and oscillator. Consensus and weighting applied. Each specialist bot inspects a different slice of the feature set, casts a directional vote, and contributes a confidence weight to the final score.
Engine edgeStrong bullish edgeBullish
Inputs: newsSentiment, dayChange
Sentiment 50/100 + price 0.9% are both mid-range.
Inputs: unusualVolume, dayChange
Volume read 21/100 with price drift 0.9% — no clear footprint.
Inputs: volatilityRisk, momentum
Vol regime 69/100 is mid-range — no edge.
Inputs: pctOfRange, trendVelocity
Near range top — needs fresh catalyst to break out.
Inputs: newsSentiment, weekChange
Sentiment 50/100 vs week change 1.9% are in agreement — no divergence edge.
Inputs: vsSma50, momentum
Price 13.6% over 50d SMA with momentum confirming — uptrend intact.
Inputs: momentum, trendVelocity
Oscillator at 78 — neutral zone.
Inputs: momentum, dayChange, vsSma50
Momentum 83/100 with a positive tape and price not below the 50d SMA — breakout continuation.
Inputs: newsSentiment, weekChange
News 50/100 and weekly change 1.9% do not create a clean follow-through read.
Inputs: unusualVolume, trendVelocity
Volume 21/100 is quiet while trend velocity stays firm — supply looks thin.
Inputs: volatilityRisk, pctOfRange, momentum
Volatility 69/100 does not give a clean compression read.
Inputs: pctOfRange, dayChange, weekChange
Price is near the top of its 52-week range and the tape still confirms higher.
Inputs: newsSentiment, momentum, weekChange
Sentiment 50/100 and momentum 83/100 are not aligned enough for a clean read.
Inputs: vsSma50, momentum, trendVelocity
Price is above the 50d SMA and both momentum and trend velocity are holding up.
Inputs: momentum, trendVelocity, weekChange
Oscillator at 78 does not show a rebound edge.
Why the ensemble agrees
- Momentum 83/100 confirmed by trend velocity 72/100.
- Momentum 83/100 with a positive tape and price not below the 50d SMA — breakout continuation.
- Price is near the top of its 52-week range and the tape still confirms higher.
Bull Case
- Momentum 83/100 confirmed by trend velocity 72/100.
- Price 13.6% over 50d SMA with momentum confirming — uptrend intact.
- Momentum 83/100 with a positive tape and price not below the 50d SMA — breakout continuation.
Bear Case
- No bearish case in the sources.
Latest Market Headlines
Headline titles only, from the publisher named on each card. Each links to the original story.
No current headlines passed the relevance filter. The watch panel above still shows the catalysts and risk factors being tracked.
Key stats
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Market cap
- $25.68B
- 52-week range
- $609.35/$430.02
- Volume
- 518,613
- Avg volume
- 749,556
- Analyst 1-yr target
- $696.00
- Exchange
- NASDAQ-GS
Source: Nasdaq public quote data. Research only.
Insider trades
0 buys · 35 sells by UTHR insiders (SEC Form 4 filings)
- SELL Rothblatt Martine A Chairperson & CEO · 2026-10-23$1.03M
- SELL Rothblatt Martine A Chairperson & CEO · 2026-10-23$750K
- SELL Rothblatt Martine A Chairperson & CEO · 2026-10-23$701K
- SELL Rothblatt Martine A Chairperson & CEO · 2026-10-23$550K
- SELL Rothblatt Martine A Chairperson & CEO · 2026-10-23$461K
- SELL Rothblatt Martine A Chairperson & CEO · 2026-10-23$443K
Earnings Intelligence
Next
Nov 4, 2026
Estimate
$5.85
Actual
$7.27
- • Last report Aug 5, 2026 (Jun 2026): EPS $7.27 vs $6.82 expected, +6.6% surprise.
- • Beat estimates in 3 of the last 4 quarters.
- • Next report expected Nov 4, 2026, consensus EPS $5.85 (Zacks estimate via Nasdaq; the company may confirm a different date).
Risk Warnings
- • Signals are model output from public data, not personalized investment advice.
- • High volatility — position sizing and stops matter more here.
- • Confirm liquidity, spreads, and your own thesis before acting.
UTHR questions
What is the MarketPicks AI signal for United Therapeutics Corporation stock (UTHR)?
As of Nov 1, 10:57 PM ET, the ensemble reads bullish on UTHR — bullish — 6 of 16 bots up, with 6 bull, 0 bear and 10 hold votes from 16 specialist bots. Research only, not investment advice.
What is the latest UTHR price on MarketPicks?
UTHR was $598.72 on the latest quote (Nov 1, 10:57 PM ET), +0.87% since the previous close. Quotes can be delayed.
What do the momentum and trend scores for UTHR mean?
Scores run from 0 to 100, with 50 neutral. UTHR shows momentum 83/100, trend velocity 72/100 and volatility risk 69/100, with news sentiment at 50/100.
Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.